The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Management of drug-resistant tuberculosis
Open accessAbstract
Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%. Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable outcomes than those treated for drug-susceptible tuberculosis. Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes. Some clinical trials are evaluating 6-month regimens to simplify management and improve outcomes of patients with multidrug-resistant tuberculosis. Here we review optimal diagnostic and treatment strategies for patients with drug-resistant tuberculosis and their contacts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spruit, M. A., Singh, S. J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., Hill, K., Holland, A. E., Lareau, S. C., Man, W. D.-C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1634st · Cited by 3,938
Treatment of Multidrug-Resistant Tuberculosis
Wood, A. J. J., & Iseman, M. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291108 · Cited by 706
Dorman, S. E., Schumacher, S. G., Alland, D., Nabeta, P., Armstrong, D. T., King, B., Hall, S. L., Chakravorty, S., Cirillo, D. M., Tukvadze, N., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30691-6 · Cited by 689
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Self-citationAhmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationMack, U., Migliori, G. B., Sester, M., Rieder, H. L., Ehlers, S., Goletti, D., Bossink, A., Magdorf, K., Hölscher, C., Kampmann, B., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00120908 · Cited by 591
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
The CRyPTIC Consortium and the 100, 0. G. P. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800474 · Cited by 500
Theron, G., Zijenah, L., Chanda, D., Clowes, P., Rachow, A., Lesosky, M., Bara, W., Mungofa, S., Pai, M., Hoelscher, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62073-5 · Cited by 433
Self-citationTiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Cited by
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119430 · Cited by 578
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Metadata
- Authors
- Lange, C., Dheda, K., Chesov, D., Mandalakas, A. M., Udwadia, Z., & Horsburgh, C. R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 394
- Issue
- 10202
- Pages
- 953-966
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2973028036
- Cited by
- 299
- References
- 53
- FWCI
- 22.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of drug-resistant tuberculosis. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31882-3
- The paper
- Lange, C., Dheda, K., Chesov, D., Mandalakas, A. M., Udwadia, Z., & Horsburgh, C. R. (2019). Management of drug-resistant tuberculosis. The Lancet. https://doi.org/10.1016/s0140-6736(19)31882-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
